Division of Inherited Metabolic Diseases, Centre for Childhood and Adolescent Medicine, University Hospital Heidelberg, Germany

1. Respondent Profile	
1.1 Please indicate the type of organisation on behalf of which you are responding to this consultation:	Healthcare provider
Please indicate what type:	Hospital
Please indicate for what the administration is responsible:	
1.1.1. Other (please specify):	
1.2 Please indicate the name of your organisation or centre:	Division of Inherited Metabolic Diseases, Centre for Childhood and Adolescent Medicine, University Hospital Heidelberg, Germany
1.3 Please indicate the country where your organsation/centre is located/has its headquarters or main representative office in Europe:	DE
1.4 Please indicate the number of EU Member States and EEA countries (Norway, Iceland, Lichtenstein) and accessing country (Croatia) in which your organisation conducts business/is represented:	1
1.5 If need be, can we contact you by e-mail to obtain further information on your submission?	Yes
1.5.1 Please provide an e-mail address where we can contact you:	stefan.koelker@med.uni-heidelberg.de
1.6 Please provide us with a contact person (incl jobtitle and daytime phone number):	Prof. Dr Stefan Kölker Head, Division of Inherited Metabolic Diseases Consultant, Pediatric Metabolic Medicine +49-6221-564002 (Central switchboard)
1.7 Please provide additional contact details if needed:	

	centres of excellence/reference (COE) and healthcare alised healthcare (HSHC).
2.1 How would you describe your organisation's knowledge of CoE and HSHC?	d Very high
2.1.1 Space for further comments:	
2.2. What aspects or domains related to the topic of CoE and HSHC would correspond to your organisation's key knowledge? (cross any that applies)	Highly specialised healthcare provision Management and organisational aspects of highly specialized healthcare Professional performance, clinical practice, quality and safety of specialized healthcare Assessment/evaluation/certification of clinical practice and healthcare providers
2.2.1. Space for further comments:	
2.3 Is highly specialised healthcare a priority in your organisation's strategies and work plans?	Very high
2.3.1 Space for further comments:	
2.4. What specific field of healthcare services/specialities are most relevant for your centre/organisation's field of work?	Medical speciality
Please specify:	Metabolic ward, outclinics, and lab services
2.5. Has your organisation/centre been directly involved in the design or assessment of professional standards and criteria related with highly specialised healthcare?	Frequently
2.5.1 Please describe your role in such actions/projects:	

2.6. Has your organisation been involved in projects/activities supported by the Commission in relation with HSHC or professional and technical criteria/standards in highly specialised healthcare?	Yes
2.7. Do you have concrete examples based on your own organisation's experience or could you provide us with references or links to documents related with professional criteria and standards in highly specialised healthcare/CoE or HSHC (e.g. quality criteria, guidelines, consensus documents)?	Yes
2.7.1 Space for further comments:	Various guidelines and evidence-based consensus care protocols for inherited metabolic disease and newborn screening (available at website: www.awmf.org and www.e-imd.org)
2.8. Is your centre or unit directly involved in the management (diagnosis, treatment etc.) of highly specialised diseases or conditions?	Yes
2.9. Is your centre or unit designated or recognised as centre of reference/excellence in your country?	Yes
2.10. How has your centre been designated/recognised as centre of reference/excellence?	Based on professional recognition
2.10.1 Space for further comments:	So far, there is no formal institutional process for metabolic references centres in Germany.
2.11. Which is your area of expertice as centre of reference? (please provide your answer in free text)	Pediatric Metabolic Medicine Newborn screening
2.12 Is your centre participating currently in a network of centres of expertise?	Yes
2.13. What is the scope of the network?	International
2.14. Which kind of network?	Founded by the European Commission

2.14.1 Space for further comments:	1) European registry and network for intoxication type metabolic diseases (E-IMD), coordinator 2) European network and registry for homocystinurias and methylation defects (E-HOD), associate partner
2.15. Would you be interested in applying to the process to be considered Centre of Excellence of the future European Reference Network? (1 = not interested at all, 5 = very interested)	5
2.15.1 Space for further comments:	

3. Proposed criteria for ERN (scope, general and specific criteria)

.1.1. Need of highly specialised healthcare	5
.1.1.1. Complexity of the diagnosis and treatment	5
3.1.1.2. High cost of treatment and resources	3
3.1.1.3. Need of advanced/highly specialised medical equipment or infrastructures	5
3.1.2. Need of particular concentration of expertise and resources	5
3.1.2.1. Rare expertise/need of concentration of cases	5
3.1.2.2. Low prevalence/incidence/number of cases	5
3.1.2.3. Evaluated experiences of Member States	4

3.1.3. Based on high-quality, accessible and cost-effective healthcare	5
3.1.3.1. Evidence of the safety and favourable risk-benefit analysis	5
3.1.3.2. Feasibility and evidence of the value and potential positive outcome (clinical)	5
3.1.4. Do you recommend any additional criteria or option that would effectively address the issue?	No
3.1.5. Would you prioritise or suggest any concrete disesase or group of diseases to be addressed by the future ERN according to the above criteria?	
3.1.5.1 Explain your proposal in free text:	Inherited Metabolic Diseases, a growing group of > 450 rare, complex conditions. Patients need highly specialised care. Many of these diseases are treatable if they are diagnosed in newborns.

3.2. General criteria of the centres wishing to join a European Reference Network	
3.2.1. Organisation and management	5
3.2.2. Patients empowerment and centered care	5
3.2.3. Patient care, clinical tools and health technology assessment	5
3.2.4. Quality, patient safety and evaluation framework policies	5
3.2.5. Business continuity, contingency planning and response capacity	4
3.2.6. Information systems, technology and e-health tools and applications	4

3.2.7. Overall framework and capacity for research and training	5
3.2.8. Specific commitment of the management/direction of the centre/hospital to ensure a full and active participation in the ERN	5
3.2.9. Do you recommend any additional option that would effectively address the issue?	No
3.2.9.1. Space for further comments:	

3.3. Specific criteria regar	ding the areas of expertise
3.3.1. Competence, experience and good outcomes and care	5
3.3.2. Specific resources and organisation:	5
3.3.2.1. Human resources	5
3.3.2.2. Team/centre organisation	5
3.3.2.3. Structural conditions	5
3.3.2.4. Specific equipment	5
3.3.2.5. Presence and coordination with other required complementary units or services	5
3.3.3. Patient care pathways, protocols and clinical guidelines in the field of expertise	5
3.3.4. External coordination, care management and follow-up of patients	4
3.3.5. Research, training, health technology assessment in the field of expertise	4

3.3.6. Specific information systems	4
3.3.7. Do you recommend any additional criteria or option that veffectively address the issue?	would No
3.3.7.1. Space for further comments:	The establishment of highly specialised care also requires training pathways for healthcare professionals. These are often not yet available or show a significant variation in EU MS.